Eli Lilly is seeking an Emergency Use Authorization (EUA) for its monoclonal antibody LY-CoV555 for treatment of high-risk patients diagnosed with mild-to-moderate COVID-19.

LY-CoV555, or bamlanivimab, which is being developed with Vancouver-based AbCellera, is a neutralizing antibody that targets the coronavirus’ spike protein.

Lilly says that trial data showed LY-CoV555, both as a monotherapy and in combination with another neutralizing antibody, LY-CoV016, is an effective treatment for high-risk COVID-19 patients.